NIKKEI 225
38,460.08 +907.92 (+2.42%) HANG SENG
17,201.27 +372.34 (+2.21%) CRUDE OIL
82.62 -0.74 (-0.89%) GOLD FUTURES
2,338.20 -3.90 (-0.17%) DOW
38,349.65 -154.04 (-0.40%) Bitcoin GBP
51,977.28 -1,680.05 (-3.13%)
QIAGEN N.V. (QIA.DE)
| Previous close | 38.92 |
| Open | 38.95 |
| Bid | 38.65 x 48300 |
| Ask | 38.67 x 51100 |
| Day's range | 38.58 - 39.10 |
| 52-week range | 33.75 - 44.81 |
| Volume | |
| Avg. volume | 643,880 |
| Market cap | 8.627B |
| Beta (5Y monthly) | 0.42 |
| PE ratio (TTM) | 26.98 |
| EPS (TTM) | 1.43 |
| Earnings date | N/A |
| Forward dividend & yield | 1.18 (2.94%) |
| Ex-dividend date | 30 Jan 2024 |
| 1y target est | 47.90 |
ZacksUnveiling Qiagen (QGEN) Q1 Outlook: Wall Street Estimates for Key Metrics
Evaluate the expected performance of Qiagen (QGEN) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
GlobeNewswireQIAGEN N.V. to release results for Q1 2024 and hold webcast
Venlo, The Netherlands, April 09, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the first quarter 2024. Press release date / time: Monday, April 29, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Tuesday, April 30, at 15:00 Frankfurt time / 14:00 London time / 09:00 New York time. Three options for joining the conference call Register for call back connection - C
ZacksQIAGEN (QGEN) Boosts Cancer Research Suite With New Launches
QIAGEN's (QGEN) new products, coupled with the IVD version of QIAGEN's digital PCR platform QIAcuity, are planned to be released in mid-2024.
